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Role for RANK/RANKL Pathway
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Maria Orengo2, Anna Maria Massone6, Carlo Emanuele Neumaier10, Daniela de Totero11, 
Paolo Giannoni12, Matteo Bauckneht3, Michele Pennone2, Claudya Tenca4, Elena Gugiatti4, 
Alessandro Bellini3, Anna Borra3, Elisabetta Tedone9, Hülya Efetürk2,3, Francesca Rosa10, 
Laura Emionite13, Michele Cilli13, Davide Bagnara4,14, Valerio Brucato15, Paolo Bruzzi16, 
Michele Piana6,17, Franco Fais4,7 & Gianmario Sambuceti  2,3
Skeletal erosion has been found to represent an independent prognostic indicator in patients with 
advanced stages of chronic lymphocytic leukaemia (CLL). Whether this phenomenon also occurs in 
early CLL phases and its underlying mechanisms have yet to be fully elucidated. In this study, we 
prospectively enrolled 36 consecutive treatment-naïve patients to analyse skeletal structure and bone 
marrow distribution using a computational approach to PET/CT images. This evaluation was combined 
with the analysis of RANK/RANKL loop activation in the leukemic clone, given recent reports on its role 
in CLL progression. Bone erosion was particularly evident in long bone shafts, progressively increased 
from Binet stage A to Binet stage C, and was correlated with both local expansion of metabolically 
active bone marrow documented by FDG uptake and with the number of RANKL + cells present in the 
circulating blood. In immune-deficient NOD/Shi-scid, γcnull (NSG) mice, administration of CLL cells 
caused an appreciable compact bone erosion that was prevented by Denosumab. CLL cell proliferation 
in vitro correlated with RANK expression and was impaired by Denosumab-mediated disruption of the 
RANK/RANKL loop. This study suggests an interaction between CLL cells and stromal elements able to 
simultaneously impair bone structure and increase proliferating potential of leukemic clone.
B-cell chronic lymphocytic leukaemia (CLL) is the most frequent leukaemia in western countries1,2. It mainly 
occurs in the elderly, with 85–90% of patients being diagnosed after the age of 503. Almost one third of CLL 
patients do not require any treatment during the entire disease course4,5. However, in the majority of patients CLL 
aggressiveness increases at a variable time after diagnosis, because of the combination of antiapoptotic mecha-
nisms5 and enhanced proliferating activity6–10. Factors triggering this progression are still not fully clarified and 
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no treatment has shown capability to halt disease progression in the asymptomatic phase11,12. However, there is 
accumulating evidence that the TNF superfamily member Receptor Activator of Nuclear Factor Kappa-B Ligand 
(RANKL) and its receptor RANK do play a role in CLL clone upkeep and in the progression of other B-cell related 
hematologic malignancies13–18. This pathway is indeed crucial in the immune system’s physiological development, 
as mice lacking RANK show absent lymph node development and impaired B-Cell differentiation19. In CLL, 
the recognized abundance of surface RANKL is often paralleled by an aberrant RANK expression14–16. On one 
side this phenomenon leads to an upregulation of interleukin-8 expression/release improving clone survival and 
expansion14. On the other hand, the capability of this same axis to promote osteoclast commitment in circulating 
monocytes enhances bone reabsorption possibly leading to the release of a variety of growth factors into the bone 
microenvironment as recognized in multiple myeloma and bone metastases15,20,21.
Using a dedicated software, capable of quantifying volumes of compact (CBV) and trabecular bone (IBV) 
from X-ray CT slices22–24, we already documented a selective erosion of compact bone, which managed to predict 
patients’ disease-specific survival, providing prognostic information independent from the commonly employed 
biomarkers23. Similarly, Lagenberg et al. reported the occurrence of pathological fractures in a patient with 
chronic lymphatic leukaemia without disease progression25.
The present study was designed to verify whether this alteration characterizes CLL per se or only occurs 
in its advanced stages and involves RANK/RANKL loop. Accordingly, we prospectively recruited a cohort of 
treatment-naïve CLL patients to simultaneously evaluate global skeletal volume (SV) and structure, active bone 
marrow (RBM) distribution and metabolism as well as clonal activation by RANK/RANKL pathway. The data 
obtained represents evidence about the role of this paracrine/autocrine loop in skeletal derangement and prolif-
erating activity of the CLL neoplastic clone.
Results
Clinical staging and demographic characteristics. According to the clinical characteristics reported 
in Table 1, the study population was divided into 16, 12 and 8 patients as Binet A, B and C stages, respectively. 
Age, sex distribution and time elapsed from diagnosis to imaging were not significantly different in the three risk 
classes. Similarly, molecular indexes of disease aggressiveness were not significantly associated with Binet stages. 
In fact, >30% CD38+ cell prevalence was superimposable (50%) in all three classes while IgHV mutation in <2% 
clonal cells classified as high risk 25%, 42% and 63% subjects in Binet A, B and C stages, respectively (p < 0.01) 
(Table 1). Binet C stage was obviously associated with significantly lower levels of hemoglobin as well as with 
higher counts of both circulating leucocytes and CD19+ cells.
PET/CT scans did not show lesions with elevated glucose metabolism in any patient. Lymph nodal enlarge-
ment in > 2 stations was observed in 30/36 patients including 10/16 Binet A subjects (62%). However, these 
findings were not considered to modify clinical staging, according to the published guidelines26. At subsequent 
follow up (duration 14–27 months) no patient developed further neoplasia or chronic inflammatory conditions.
Skeletal erosion and bone marrow glucose metabolism. Volume of the entire skeleton was compara-
ble in patients and in control subjects (66 ± 11vs 66 ± 9 ml/Kg IBW, respectively, p = ns). Nevertheless, CLL was 
associated with a significant erosion of compact bone paralleled by an expansion of IBV. In fact, IBV/SV ratio 
of the whole skeleton was higher in patients than in control subjects (39.1 ± 2% vs 32.7% ± 3.2%, respectively, 
p < 0.001, Fig. 1A). In the axial segments, this phenomenon was barely appreciable (51.1 ± 2.5% vs 47 ± 5.9%, 
respectively, p = 0.08). By contrast, it was particularly manifest in the appendicular bones (36.2% ± 2.1% in 
patients vs 28.9% ± 3.9% in controls, respectively, p < 0.001, Fig. 1B). In fact, shaft cortical thinning occurred 
in all Binet classes and showed a progressive increase from stage A to stage C (trend analysis p = 0.011, Fig. 1B). 
Finally, IBV/SV ratio was virtually independent from clinical features such as age, time elapsed from disease 
diagnosis or IgHV mutation (Suppl. Figure 1).
Average FDG uptake in RBM (defined by normalized standardized value N-SUV) was similar in CLL patients 
and control subjects (1.23 ± 0.3 vs. 1.18 ± 0.2, respectively, p = ns, Fig. 1C). However, the influence of CLL on 
BM metabolic activation was suggested by the progressive increase in FDG uptake from stage A to stage C that 
occurred in the whole skeleton and in appendicular segments (trend analysis p < 0.05) (Fig. 1C,D). This pattern 
was particularly evident in long bone shafts in which RBM N-SUV progressively increased throughout Binet 
stages to become significantly higher with respect to controls in stage C (Fig. 1D,E–G).
The patient-by-patient analysis did not document any relationship between RBM glucose consumption and 
bone erosion in the whole skeleton or in axial districts (Suppl. Figure 2). By contrast, there was a fair correlation 
(r = 0.57, p < 0.01) between IBV/SV ratio and metabolically active hematopoietic tissue in the appendicular seg-
ments (Suppl. Figure 2).
Group Number Gender F/M
AGE 
(Years)
HEIGHT 
(cm)
WEIGHT 
(Kg)
Disease 
Duration 
(Months) Hb (g/L)
WBC 
(10E9/L)
PLT 
(10E9/L)
LYMPHOCYTES 
(RELATIVE %) %CLONE
IgHV 
mutation in 
>2% cells CD38%
All 36 11/25 70 ± 12 168 ± 8 71 ± 9 34 ± 39 126 ± 22 62,58 ± 55,6 180 ± 56,5 73 ± 20,4 63,24 ± 24,9 22 (61%) 34 ± 22
Binet A 16 6/10 71 ± 13 166 ± 7 66 ± 7 35 ± 33 136,2 ± 14,9 43,7 ± 39 193,3 ± 42,8 68,4 ± 19,4 55,67 ± 21 12 (75%) 30 ± 18
Binet B 12 4/8 67 ± 12 166 ± 9 77 ± 9 39 ± 46 129,6 ± 14 61,1 ± 46,2 77,2 ± 38,9 77,2 ± 14,7 61 ± 30 7 (58%) 38 ± 24
Binet C 8 1/7 73 ± 9 172 ± 7 72 ± 10 23 ± 43 105,5 ± 26,5 102,4 ± 78,1 154 ± 86,5 75,9 ± 28,4 81,7 ± 12 3 (37%) 36 ± 25
Table 1. Clinical Characteristics of the Pateints’ Population.
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Figure 1. %IBV/SV ratio in control subjects (white) overall CLL patients (black). This latter group is subdivided 
according to Binet A (pale grey), B (grey) and C (dark grey). CLL was associated with a significant bone erosion 
(**p < 0.01 vs controls) that was independent from Binet stage when the whole skeleton was analyzed (panel 
A), while it was related to clinical disease stage in the appendicular districts (panel B). Panel C shows whole 
body RBM glucose consumption in CLL patients and control subjects. In appendicular bones (Panel D), this 
same pattern was associated with a significant progressive trend in N-SUV (p < 0.05) between the different 
Binet stages and became higher than control value in Binet C patients (*p < 0.05). Panels E-F-G: Examples of 
RBM distributions in the three Binet stages, respectively. The expansion of RBM in proximal femur shafts is 
evident only in Binet C patient (red arrows).
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CLL cells capability to impair bone structure in xenograft model. One of the possible mecha-
nisms underlying the association between clinical CLL stage and bone erosion is represented by the activation of 
RANK/RANKL pathway. To verify this hypothesis, 20 NOD-SCID IL-2R γ-chain null (NSG) female mice were 
intravenously inoculated with 8 × 107 mononucleated cells collected from peripheral blood of two CLL patients 
(n = 10 each). Prior to cell administration, a high-resolution CT (CT1) documented that femur IBV/SV was 
similar in these animals with respect to the corresponding value in 10 control mice (data not shown). Four weeks 
after inoculation, successful engraftment was confirmed by flow cytometry of peripheral blood and a second 
high-resolution CT (CT2) was performed in all groups. Thereafter, CLL mice were divided into two subgroups to 
be treated with Denosumab (5 mg/Kg once a week for three weeks, n = 10) or with saline (n = 10) for three weeks 
before a further CT scan (CT3). Finally, all mice were sacrificed and cell suspensions from the spleen, bone mar-
row (BM), and peripheral blood (PBMC) were analysed for the presence of neoplastic B-cells by flow-cytometry 
(Fig. 2A–C). Disease infiltration was documented in the spleen also by immunohistochemical analysis where 
foci of neoplastic cell infiltrates, highlighted by human CD20+ immunoreactivity, were found in association with 
patient-derived T-cells, identified as human CD3+ cells27,28 (Fig. 2D,E).
Immunofluorescence analysis documented the presence of human cells in the BM of untreated models (Suppl. 
Figure 3) and also showed the presence of a high number of cells with osteoclast appearance. By contrast, this 
finding was not observed in control mice and, more importantly, in animals treated with Denosumab (Fig. 3A–
C). Analysis of femur structure in xenograft models nicely confirmed the bone derangement observed in patients. 
In fact, the apparent bone erosion associated with CLL was evident in vivo at CT2 (Fig. 3D) and was visually 
confirmed ex-vivo by high-resolution CT images that provided a description of spatial distribution of bone tissue 
within the whole femur in 3D (Fig. 3E) and 2D reconstruction (Fig. 3F).
Overall, CLL was associated with an increase in IBV/SV with respect to sham group at CT2 (7.2% ± 1.1% vs 
4.2 ± 1.3%, respectively, p < 0.001) (Fig. 4A). In untreated CLL mice, femur IBV/SV ratio did not significantly 
change and remained higher than controls at CT3 (Fig. 4A). By contrast, Denosumab induced an apparent nor-
malization of bone structure reducing IBV/SV ratio to values significantly lower with respect to untreated mice 
(Fig. 4B) and similar to the value reached by control group during the three weeks of aging (Fig. 4A).
The role of human CLL in bone erosion was further confirmed by the observation that, one week after the last 
treatment, number of neoplastic B-cells detected in BM and spleens was significantly higher in untreated xen-
ograft models with respect to those treated with denosumab (Fig. 4C). Actually, no significant difference could 
Figure 2. Panels A–C report the detection of the presence of leukemic cells engrafted in the spleen (A), 
BM (B) and peripheral blood (PBMC, C) as h-CD45/CD19/CD5-triple positive cells by flow cytometry 
in a representative mouse injected intravenously with the PBMC cells from a CLL patient. Panels D and E 
show immunohistochemical (IHC) analysis in paraffin embedded tissue slice sections from the same spleen. 
Tissue section is analysed for the presence of the typical neoplastic foci positive for CD20 B cell marker (D) 
surrounded by autologous CD3+ T cells (E) (magnification 40x upper panels and 400x lower panels).
www.nature.com/scientificreports/
5SCIENTIFIC RePORTs | 7: 14159  | DOI:10.1038/s41598-017-12761-1
Figure 3. Panel A displays hematoxylin-eosin eosin staining of bone and bone marrow biopsy in a sham mouse 
with magnification related to the green insert. Panel B displays the same analysis in an untreated xenograft 
model (relative to the red insert): a high number of multinucleated large cells similar to osteoclasts are evident 
(white and red arrows). Panel C displays the absence of this finding in the bone marrow of a mouse subjected 
to Denosumab treatment for three weeks (blue insert). Panel D reports the original images of the right femur 
obtained by high resolution CT in a control model and in a CLL mouse, respectively. The longitudinal sections 
are represented in the middle and connected with the corresponding short axis slices in the original CT scans 
obtained in living animal. The enlargement in intrabone section is apparent. Alongside these images, Panel 
E displays a 3D representation of high resolution CT obtained ex vivo from the same femur. These images 
document a relative loss in trabecular structure as well as an irregular border of compact bone. This pattern is 
confirmed in the original 2D sections of the same microCT scan (panel F) in which compact bone erosion of 
femur shaft is detailed (bottom inserts).
www.nature.com/scientificreports/
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be found in PBMC, in which a slight increase in peripheral neoplastic cells also occurred in some denosumab 
mice, probably due to mobilization from spleen and bone marrow lymphoid tissue after treatment. Nevertheless, 
the combined evaluation of bone histology, bone structure and CLL cells bulk indicates a possible correlation 
between RANK/RANKL pathway activation and bone erosion as well as in CLL cells survival and expansion in 
lymphoid tissue.
Biological indicators of CLL – bone stroma interaction. Among the possible hormonal factors 
involved in bone erosion, osteopontin, osteoprotegerin, osteocalcin, parathyroid hormone and 1–25 OH vita-
min D showed extremely variable levels and were not considered in the analysis (data not shown). Serum level 
of cytokines related to both CLL cell proliferation and osteoclast function, namely IL8 and TNFα29,30 were only 
partially related to disease severity. In fact, IL8 concentration was extremely variable and relatively independent 
from clinical risk (Suppl. Figure 4). By contrast (and in agreement with previous studies31), TNFα progressively 
increased throughout Binet stages (3.8 ± 2.67 pg/mL vs 11.5 ± 13.2 pg/mL and 13.5 ± 10.4 pg/mL in stage A, B and 
C, respectively, p < 0.05 at trend analysis) (Suppl. Figure 4).
Percentage of RANK+/RANKL+ cells was relatively stable in the different clinical stages. However, the 
increase in circulating clonal cells throughout Binet classes was associated with an increase in absolute number 
of RANK+/RANKL+ double positive (DP) leukemic cells (1677 ± 1990 cells/mmc vs 4337 ± 4768 cells/mmc and 
10769 ± 12887 cells/mmc, in Binet A-B-C respectively, p < 0.01 at trend analysis, Suppl. Figure 4). A similar 
observation applied to total number of RANKL+ cells (3989 ± 3882 cells/mmc, vs 7639 ± 6291 cells/mmc and 
19926 ± 19354 cells/mmc, in Binet A, B and C respectively, p < 0.01 at trend analysis, Suppl. Figure 4). By con-
trast, the total number of RANK+ cells increased only in Binet C stage (Suppl. Figure 4).
Figure 4. Panel A reports column chart of % IBV/SV ratio in control mice, CLL untreated mice (CLL no 
treatment) and CLL Denosumab ones. White columns indicate bone erosion at CT2 (four weeks after CLL 
cells administration) while grey columns report the same variable at CT3. AT CT2, CLL was associated with 
a significant femur erosion (*p < 0.01 vs controls). This difference persisted in untreated mice at CT3 (three 
weeks later). By contrast, Denosumab induced a significant reduction in IBV/SV to values that were lower 
with respect to untreated mice and similar to ones of control group. Panel B, displays the individual response 
to treatment (blue lines) or placebo (red lines) from CT2 to CT3. Denosumab caused a significant reduction 
of IBV/SV. Panel C summarizes the effect of in vivo denosumab treatment on human neoplastic B-cells (h 
CD45/CD5/CD19- positive cells). Percentage of CLL cells was significantly lower in denosumab treated mice 
compared to controls treated with saline (CTR) in BM and spleen. The mean and SEM of 19 mice injected with 
CLL cells from two different cases are shown (Mann-Whitney test). Panel D displays the direct correlation 
between %RANK+ B cells (X axis) in peripheral blood of each patient and actively proliferating cells indexed 
by HDF (Y axis). Panel E: displays the in vitro reduction in HDF induced by Denosumab. Panel F: displays the 
direct relationship between %RANK+ cells (X axis) and Denosumab effect on HDF.
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To further highlight the role of RANK-RANKL loop in promoting proliferation of the leukemic clone, 
the response of CLL cells to microenvironment-mimicking stimulation was tested in vitro under basal and 
RANK-RANKL-inhibited conditions. This study was performed in the 28/36 patients in whom peripheral blood 
sampling resulted in an adequate CLL cell number and included 10/16, 10/12 and 8/8 patients of stage A, B 
and C, respectively. Actively proliferating cells, measured as fraction of hyperdiploid cells (HDF), were signifi-
cantly less represented in samples harvested from Binet A patients (8.6 ± 6%) with respect to both B and C stage 
(17.5 ± 5.6 and 17.6 ± 8.2%, p < 0.05 vs Binet A, respectively). HDF displayed a considerable level of positive 
correlation with %RANK+ cells (r = 0.44, p < 0.05, Fig. 4D) and, more importantly, was significantly reduced 
when the loop RANK-RANKL was impaired. In fact, Denosumab lowered HDF from 14.5 ± 7.4% to 10.7 ± 4.7% 
(p < 0.01, Fig. 4E), regardless of patient’s Binet stage. Moreover, Denosumab effect on cell proliferation – meas-
ured according to the calculation defined in the Methods – correlated with %RANK+ cells (r = 0.52, p = 0.007, 
Fig. 4F). Altogether, the in vitro results of this patient-by-patient analysis suggested the presence of a link between 
RANK-RANKL axis and the proliferating potential of each specific CLL clone.
We thus extended the evaluation of RANK-RANKL loop to verify its capability to promote osteoclastic com-
mitment of circulating monocytes in CLL. As shown in Fig. 5A, cells with osteoclastic features (positive for TRAP 
and with 3 nuclei or more) were identifiable when autologous monocytes were cultured with CLL B cells for 25 
days. Interestingly, this response occurred spontaneously, without prior MCSF and RANKL stimulation, which 
is the classic activation to obtain osteoclasts in vitro. These same images further allow to appreciate how different 
TRAP+ cells are fusing together giving rise to more typical large multinucleated osteoclasts.
In addition, we documented the capability of conditioned media from CLL B cells cultures to increase number 
and size of osteoclasts of healthy monocytes. In these cells, osteoclast commitment could be achieved only after 
activation with MCSF + RANKL (Fig. 5B). However, adding conditioned medium derived from CLL B cells cul-
tures of 3 different patients, markedly increased osteoclast formation, as indicated by the increased percentages of 
the positive tri-nucleated TRAP+ cells in the culture wells (Fig. 5C).
Prediction of skeletal erosion and BM metabolism. As shown in Table 2, univariate regression analy-
sis documented a correlation between degree of compact bone erosion in the appendicular skeleton and disease 
aggressiveness as indicated by % CD38+ cells, TNFα and IL8 concentrations as well as BM FDG uptake. The role 
of RANK-RANKL loop became more evident at multivariate analysis in which the predictors of IBV/SV ratio 
were number of CLL RANKL+ cells, IL8 concentration and metabolic BM activation (N-SUV).
Determinants of FDG uptake within the intraosseous tissues are reported in Table 3. At univariate analysis, 
BM metabolism was strictly correlated with both TNFα levels and in vitro CLL cell proliferation, measured by 
HDF, while it was virtually independent from haemoglobin levels. However, only degree of appendicular compact 
bone erosion preserved the statistically significant correlation with RBM N-SUV at multivariate analysis.
Discussion
The major finding of the present study is that CLL is associated with significant bone erosion in all clinical stages. 
This skeletal alteration was particularly evident in long bone shafts, was documented in all risk classes, progres-
sively increasing from Binet A to Binet C, and was related to the number of CLL RANKL+ cells. Also, the same 
long bone shafts were colonized by metabolically active RBM, as documented by PET-FDG imaging. The spatial 
coherence of RBM activity and bone erosion matches the capability of human CLL cells to reproduce skeletal 
derangement in immune-deficient mice and to promote osteoclast commitment in autologous and healthy mono-
cytes. Altogether, these observations indicate the presence of an interaction between neoplastic clone and bone 
microenvironment at least partially involving RANK-RANKL loop.
CLL was associated with an array of skeletal alterations that cannot be attributed to the confounding interfer-
ence of previous therapies, since it occurred in treatment-naïve patients. Several studies on experimental models 
of leukemia and myeloma already reported an alteration of trabecular bone structure and composition in ver-
tebral bodies32,33. Similarly, our computational approach documented an expansion of IBV at the expense of a 
cortical thinning. This erosion was particularly evident in appendicular structures of our patients while it did 
not reach the statistical significance in axial skeletal segments regardless disease stage. This partial disagreement 
might probably reflect the limited spatial resolution of the low-dose attenuation-correction CT scanning proto-
col and the consequent influence of the partial volume averaging effect in bones characterized by a thin cortical 
layer22–24. This methodological limitation does not permit to ascertain whether CLL-associated bone erosion 
involves specific bone segments or rather the whole skeleton. However, this same feature confirms the robustness 
of the signal whose documentation does not require dedicated scanning procedures and high radiation burden.
Actually, shaft cortical thinning progressively increased with increasing clinical index of disease severity. This 
evidence at least partially agreed with the distribution of RBM and its correlation with Binet staging as docu-
mented by FDG uptake. Usually, RBM metabolism cannot by detected by FDG imaging in long bone shafts of 
adult humans, coherently with the concept that, in adulthood, hematopoietic activity is limited to the intraosse-
ous space of axial skeleton and the proximal epiphyses34–36. The present data do not permit to ascertain whether 
this colonization can be ascribed to the presence of the neoplastic clone or rather the expansion of normal 
hematopoietic tissue. Nevertheless, previous studies already reported a link between disease aggressiveness and 
BM metabolic activity detected at PET CT37–39. Moreover, the observed distribution pattern did not reproduce the 
usual response to myelotoxic damage or increased need of circulating blood cells40,41 that implies an activation of 
RBM in axial skeleton. Accordingly, the match between cortical thinning and BM metabolic activation in the long 
bone shafts may suggest an interaction between CLL clone and bone microenvironment. This hypothesis is sup-
ported by the analysis of xenograft models in which human CLL cells expanded IBV in mouse femurs. Similarly, 
it is confirmed by the in vitro evidence: CLL-monocytes displayed a spontaneous commitment toward large and 
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Figure 5. In panel A, cells with features of osteoclasts, as determined by TRAP positivity and ≥3 nuclei/cell 
(red arrows), were observed after co-cultures of monocytes with autologous CLL B cells for 25 days, without 
any monocytes pre-activation. Details at high magnification are displayed in the green box. In panel B, 
monocytes sampled from a healthy donor differentiated toward osteoclastic phenotype after activation with 
RANKL and MCSF. In panel C, number and the size of osteoclasts, from healthy monocytes pre-activated 
with MCSF + RANKL, appeared enhanced when conditioned media (CM) of CLL B cells cultures were added. 
Images are relative to experiments performed with CM from 3 representative CLL cases. In Panel D, histograms 
depict the average (±SD) percentage of tri-nucleated TRAP+ cells counted per field in all different experimental 
conditions: control CD14+ purified monocyte culture; +BE117, +FA35, +FW16, +MG37, +VG34: control 
monocytes cultured with the addition of the corresponding CM of CLL B cells. Nominal p values are indicated; 
n.s.: not significant. A minimum of total 3000 cells was counted for each culture condition and experiment.
www.nature.com/scientificreports/
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multinucleated cells. Although some large cells may represent “nurse-like” CLL cells42–44, a substantial number 
of osteoclasts are clearly identifiable based on the presence of 3 or more nuclei together with TRAP positivity44.
Altogether, these findings indicate that CLL cells may disrupt the delicate osteoclastic/osteoblastic balance 
eventually altering the physiological bone remodelling.
Regarding the mechanisms underlying this interaction, several studies already documented an aberrant 
RANKL expression in different B cell malignancies such as CLL, multiple myeloma and follicular lymphoma13–21. 
Actually, Secchiero et al. reported that RANK/RANKL interaction potently increases the release of IL-8 as a factor 
able to promote clone proliferation and resistance to apoptotic signals in CLL14. Similarly, Borge et al. described a 
high production of soluble RANKL by leukemic cells in a CLL patient with bone destruction45.
In the present study, the role of RANK/RANKL loop was confirmed by several observations. In xenograft 
models, CLL administration was associated with a thinning of femoral cortex. Due to the nature of xenograft 
model and the role of activated T cells in CLL engraftment27, the present data do not permit to verify whether 
this phenomenon was selectively caused by the neoplastic clone or by the inflammatory condition favored by 
the co-administered T lymphocytes46 even in the absence of an overt xenograft versus host reaction (X-GVHD). 
Nevertheless, antagonizing human RANKL with Denosumab markedly reduced the number of osteoclasts visible 
at histology, diminished femur bone erosion and restored the ratio between trabecular and compact bone vol-
umes close to the control value documenting the role of RANK/RANKL axis and its capability to activate oste-
oclast commitment in circulating monocytes20,21. On the other hand, in vitro proliferating activity of stimulated 
Univariate analysis Multivariate analysis
Non standardized coefficient Standardized coefficient
Non standardized 
coefficient Standardized coefficient
B
Standard 
error Beta t p B
Standard 
error Beta t p
RANK+ cell 
number 1.709 × 10
-7 0.000 0.104 0.6 0.523 — — — — —
RANK+-
RANKL+ cell 
number
8.806 × 10−7 0.000 0.192 1.124 0.269 — — — — —
% cells in 
S + G2M cycle 
phase
0.001 0.001 0.264 1.398 0.174 — — — — —
Hemoglobin −0.041 0.026 −0.255 −1.538 0.133 — — — — —
TNF-alpha 0.992 0.001 0.461 2.98 0.005 — — — — —
CD19+ cells 1.464 × 10−6 0.000 0.18 1.068 0.293 — — — — —
% CD38+ cells 0.001 0.000 0.41 2.581 0.014 — — — — —
IL8 0.001 0.000 0.348 2.035 0.051 0.001 0.021 0.449 3.171 0.001
BM FDG uptake 
(N-SUV) 0.061 0.017 0.529 3.632 0.001 0.060 0.015 0.542 3.971 0.001
RANKL+ cell 
number 7.571 × 10
−7 0.000 0.258 1.512 0.14 0.000 0.000 0.376 2.62 0.016
Table 2. Prediction of appendicular bone erosion: uni- and multivariate analysis.
Univariate analysis Multivariate analysis
Non standardized coefficient Standardized coefficient
Non standardized 
coefficient Standardized coefficient
B
Standard 
error Beta t p B
Standard 
error Beta t p
RANK+ cell number 7.37 × 10−7 0 0.052 0.299 0.767 — — — — —
RANK+-RANKL+ 
cell number 5.29 × 10
−6 0 0.134 0.777 0.443 — — — — —
% cells in S + G2M 
cycle phase 0.031 0.008 0.557 3.86 0.001 — — — — —
Hemoglobin −0.003 0.002 −0.227 1.257 0.184 — — — — —
TNF-alpha 0.015 0.004 0.507 3.383 0.002 — — — — —
CD19+ cells 1.431 × 10−6 0 0.204 1.215 0.233 — — — — —
% CD38+ cells 0.003 0.002 0.205 1.223 0.23 — — — — —
IL8 0.001 0.003 0.067 0.366 0.717 — — — — —
RANKL+ cell 
number 5.32 × 10
−6 0 0.211 1.223 0.23 — — — — —
Appendicular 
skeleton IBV/SV 4.56E + 00 1.257 0.529 3.632 0.001 5.507 1.471 0.607 3.744 0.001
Table 3. Prediction of FDG uptake in active bone marrow: uni- and multivariate analysis.
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CLL clone was directly correlated with the prevalence of RANK + cells and was significantly reduced by the same 
Denosumab. Accordingly, the present data suggest that RANK/RANKL loop activation – promoted by either 
CLL clone or autologous T lymphocytes – might extend its role to represent a factor enhancing CLL proliferating 
potential beyond its recognized anti-apoptotic effect.
Finally, the role of this loop was confirmed in vivo by the uni- and multivariate analyses that indicated 
RANKL+ cell number as a predictor of bone erosion together with RBM metabolic activity, % of CD38+ CLL cells 
and serum levels of both TNFα and IL8.
In conclusion, the present study confirms the presence of a bone erosion in a small prospectively enrolled pop-
ulation of consecutive, treatment-naïve CLL patients. This skeletal derangement is present in all disease stages, it 
becomes more evident with increasing clinical risk index and particularly involves long bone shafts at least par-
tially recolonized by active BM. This finding indicates that the interaction between leukemic clone and microen-
vironment might play a significant role in the natural history of CLL. This interaction at least partially involves 
RANK-RANKL pathway whose activation, if confirmed, may represent a possible therapeutic target. Similarly, 
this same relationship can suggest that bone erosion (if properly confirmed in larger populations studies) could 
represent a surrogate end-point for testing the efficacy of new treatments.
Methods
Patient Recruitment. Enrolments included 36 consecutive previously untreated CLL patients (11 females, 
mean age 70 ± 12 years; range 43–91 years). CLL diagnosis had been established made from peripheral blood cells 
immunophenotype and staging was performed according to Binet classification26. All patients had not previously 
received therapy or had been free from therapy for at least 6 months. Exclusion criteria included history or con-
comitant presence of other solid or hematologic neoplasm, previous prolonged corticosteroid therapy, uncon-
trolled diabetes and active or chronic infection as well as autoimmune disease. Thirty-six age- and sex-matched 
healthy subjects, randomly selected from a published normalcy database, served as controls22. The study was 
approved by the Ethics Committee of IRCCS San Martino/IST Hospital. All patients signed an informed consent 
prior to study inclusion. All experiments were performed in accordance with relevant guidelines and regulations.
PET/CT acquisition and reconstruction. All patients underwent 18F-fluorodeoxyglucose (FDG) PET/
CT imaging after a minimum of 12 hours of fasting. Before the study, height and weight were measured, ideal 
body weight (IBW) was calculated according to Robinson formulation47 and serum glucose level was assessed 
( ≤ 1.5 g/L). FDG (4.8–5.2 MBq per kilogram of body weight) was intravenously administered and, after min-
imum 60–75 of resting in the waiting room, scanning was performed in 3D mode from vertex to toes in an 
arms-down position, using an integrated PET/CT scanner (Hirez; Siemens Medical Solutions, Knoxville, US). 
PET raw data were reconstructed by means of ordered subset expectation maximization (OSEM, three iterations, 
16 subsets) and attenuation correction was performed using CT data. The transaxial field of view and pixel size 
of the reconstructed PET images were 58.5 cm and 4.57 mm, respectively, with a 128 × 128 matrix. A 16–detec-
tor row helical CT scan was performed with non-diagnostic current and voltage settings, with a gantry rotation 
speed of 0.5 second and a table speed of 24 mm per gantry rotation. The entire CT data set was fused with the 
three-dimensional PET images by using an integrated software interface (Syngo; Siemens, Erlangen, Germany).
Image analysis. Image analysis was performed according to the previously validated method22–24. In brief, 
the application sequentially identifies and quantifies compact (CBV) and trabecular bone volume (IBV) in all 
transaxial CT images, using the appropriate attenuation characteristics of these two tissues. Skeletal erosion was 
assessed by measuring the ratio between trabecular and total skeletal volume (IBV/SV, where SV is the sum of 
IBV and CBV). The computational analysis was first carried out on the whole skeleton; then segmental analysis 
was performed on axial skeleton (vertebral bodies and sternum) and appendicular long bone shafts. All volu-
metric data were normalized according to ideal body weight (IBW). FDG uptake within IBV was thus analysed 
to estimate the volume of red BM (RBM) defined by a standardized uptake value (SUV) ≥ 1.1122. Finally, overall 
metabolic activity of RBM was corrected for blood-pool tracer concentration to obtain a normalized metabolic 
index (N-SUV).
Analysis of Biomarkers and Soluble Mediators. A 50-ml venous blood example was obtained before 
injection of the tracer. CLL cells were isolated from patients’ peripheral blood by means of Ficoll-Hypaque 
(Seromed, Biochrom) density gradient centrifugation. Clonal cell number was estimated by the measurement 
of CD5/CD19/CD23 triple positive B-cells that was determined by direct immunofluorescence with mon-
oclonal antibodies (mABs) to CD19-FITC (BD Biosciences Pharmigen, San Josè California, USA), CD23-PE 
(BD Biosciences), and CD5-PC5 (Beckman Coulter Immunotech, Marseille, France). CD38 expression status 
was tested using flow cytometry analysis by triple staining with CD19 FITC (BD Biosciences), CD38 PE (BD 
Biosciences), and CD5 PC5 (Beckman Coulter) mABs. CLL clones were defined as CD38+ when CD38 was 
expressed on > 30% of the leukemic clone48. IGHV mutational status was determined as previously described49.
Expression of both RANK and RANKL on cellular surface was assessed by means of flow-cytometry analy-
sis using a combination of monoclonal antibody anti-human CD19-FITC (BD Biosciences), RANK-PE (R&D 
System, clone#80704), CD5-PE-vio770 (Milteny), RANKL-APC (Biolegend, clone MIH24). Presence of these 
markers on clonal elements permitted to estimate the fraction of CLL cells positive for RANK/RANKL (double 
positive, DP), RANK+ and RANKL+ cells. Each fraction was multiplied by the absolute number of CD5+CD19+ 
to obtain the total number of cells/mmc. Flow cytometry analysis was performed by FACSCanto (BD Biosciences) 
and DIVA 6 software (BD Biosciences).
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In the same blood sample, serum levels of TNFα and IL-8 were measured using Millipore’s Milliplex 
MAP Human Bone Magnetic Bead Kit and acquired by MAGPIX instrumentation (#HBNMAG-51K and 
HCYTOMAG-60K).
Cultural Analysis. In vitro cultures were set up by co-culturing CLL cells and CD40L+ murine fibroblasts 
in the presence of IL-4. Inhibition of RANK-RANKL loop was achieved by the addition of the human mono-
clonal anti-RANKL antibody Denosumab (Xgeva, Amgen) to stimulated CLL cultures at a concentration of 105 
micrograms/ml (730 nM). Cell vitality was measured by flow cytometry (FACS Calibur, Becton Dickinson, San 
Jose, CA, USA) through propidium iodide exclusion assays and defined as vital cell percentage after 96 hours in 
unstimulated cultures. Cell proliferation was measured by flow cytometric DNA content histograms as previ-
ously described50 and defined by the % of cells in S + G2M cell cycle phases (hyper diploid fraction, HDF) after a 
five-days activation. Response to Denosumab was defined by the formula:
=
−Denosumab Response HDF HDF
HDF (1)
Control Denosumab
Control
Experimental reproduction of skeletal erosion pattern caused by CLL. To evaluate the interac-
tion between CLL and bone stroma, 20, six to eight-week-old female NOD-SCID IL-2R γ-chain null (NSG) 
mice (The Jackson Laboratory), a xenograft model for CLL growth in vivo27,28, were housed in sterile enclo-
sures under specific pathogen-free conditions. All mice were intravenously inoculated with 8 × 107 peripheral 
blood cells sampled from two CLL patients (n = six each, respectively) while 10 further mice served as control 
group. All procedures involving animals were performed in respect of the current National and International 
regulations and were reviewed and approved by the Licensing and Animal Welfare Body of the IRCCS-AOU 
San Martino-IST National Cancer Research Institute, Genoa, Italy. Hind limb high-resolution CT scans (GE 
Lightspeed pro32) were performed at week #2, #6 and #9 post-xenograft according to the following parameters 
(40 mA, 140 kV, DFOV 9. 6 cm, SFOV 32 cm, thickness of slices 0.625 mm). After confirming a successful engraft-
ment at TC2, CLL mice was divided into two subgroups: The first subgroup (n = 10) was treated with Denosumab 
(5 mg/Kg once a week for three weeks consecutively), while the remaining (n = 10) did not receive any treatment. 
Reoriented slices of both femurs were analyzed with the same algorithm used for human skeleton analysis to 
estimate SV, IBV and CBV. After the sacrifice, the right femur was isolated in the last animal of both xenograft and 
control groups to be scanned using a high-resolution micro-TC (Bruker SkyScan 1272) at a spatial resolution of 
4 µm in all three spatial dimensions.
In order to exclude infection by human CMV quantitative determination of CMV DNA was performed by 
real-time PCR on frozen mice plasma (pulled for groups of treatment) or serum patients’ using the CMV HHV-6, 
7, 8 amplification Kit (Argene, bioMérieux,Varilhes, France) as recommended by the manufacturer’s instructions. 
Extraction and amplification steps were performed by DNA extraction Kit (Argene) and QUIA AMP DNA Blood 
mini KIT (Quiagen), (Argene). Samples were run in Rotor Gene 3000 instrument.
Bone histology and immunofluorescence. Lower limbs of each animal were dissected, cleared of skin 
and other soft tissues, washed in phosphate-buffered saline (PBS) and fixed in paraformaldehyde (4% in PBS) for 
two days at 4 °C. Untill further processing, specimens were maintained in 70% Ethanol. Subsequently specimens 
were rinsed in PBS and decalcified in Osteodec (Bio-Optica S.p.A., Milan, Italy; cat. N. 05-MO3005) for two days, 
changing the decalcifying solution every 12 hrs, at RT, and dehydrated by subsequent washings in 70%, 90%, 95% 
and 100% Ethanol (two hours each). After one overnight in Cedar oil (Merck KGaA, Darmstad, Germany; cat. 
N. 106965), specimens were included in paraffin, with standard procedures. Sample murine femurs were then 
cut orthogonally to the bone main axis, separating epiphyses from diaphysis, and cut again in halves. Standard 
re-inclusion procedures were performed to obtain final sections for subsequent stainings.
Sections (10 μm thickness) were de-waxed and re-hydrated with standard procedures and finally washed 
in PBS for 15 min. Sections were stained with Meyer’s hematoxylin (Bio-Optica S.p.A., Milan, Italy; cat. N. 
05-MO6002) for 5 minutes, rinsed under tap water for 5 minutes and stained again with a freshly prepared 
Eosin-Erythrosine solution (0.2% in water; Eosin and Erythrosine: Merck KGaA, Darmstad, Germany; cat. N. 
115935 and N. 115936, respectively). Subsequent dehydration was performed in ethanol (95%, 100%, three times 
for 5 minutes each) and ultimately in xilol. Stained sections were mounted with Eukitt hardening-mounting 
medium (Bio-Optica S.p.A., Milan, Italy; cat. N. 09–00500).
For immunostaining, de-waxed sections were re-hydrated, washed in PBS, permeabilized for 10 minutes at RT 
(permeabilization solution: 0.1% Triton X-100; 0.1% Na-citrate, in PBS) and pre-incubated with goat anti-serum 
for 30 min at RT to block aspecific sites. After a brief wash in TBS buffer (20 mM Tris/HCl; 0.5 M NaCl; 0.1% 
Tween20; bovine serum albumin 3%), sections were incubated overnight at 4 °C with an anti-human mitochon-
dria antibody (Acris GmbH, Germany; cat. N. BM608; 1:200 in TBS). Sections were then washed (3 times for 
5 minutes each) and challenged with a goat anti-mouse Fluorescein (FITC)-conjugated secondary antibody 
(Jackson Research Labs. Inc.; West Groove, PA, USA; cat. N. 115-095-146) for 3 hrs at 4 °C.
Images were acquired with a Nikon Digital Sight DS-5Mc camera, mounted on an Olympus BX5 1 fluores-
cence microscope, using Nikon imaging software NIS-Elements F, release 2.20.
Differentiation of Osteoclasts from CLL-monocytes co-cultured with leukemic B cells or from 
allogeneic monocytes of healthy donors cultured with conditioned media from CLL B cells cul-
tures. To define whether CLL B cells may affect differentiation of autologous monocytes toward osteoclasts 
we cultured PBMCs from CLL patients at 2 × 106 /ml/well in 24 well plates. Attached cells were gently washed 
with Phosphate Buffered Saline (D-PBS; Dulbecco’s Phosphate Buffered Saline; EuroClone, cat. n. ECB4004L) and 
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subsequently stained for Tartrate Resistant Acid Phosphatase (TRAP) by the use of a commercial kit (Leukocyte 
Acid Phosphatase (TRAP) Kit; Sigma cat. N. 387A-1Kit), following manufacturer’s instructions. The presence 
and the number of osteoclast-like TRAP+ multinucleated (3 or more) cells was determined visually on an opti-
cal inverted microscopy (Olympus CKX41) equipped with a Nikon Digital Sight DS-U1 camera and the Nikon 
NIS-Element F 2.0 imaging software. Experiments were performed in duplicate and at least 3 images for each 
well were acquired. Images were then scored for tri-nucleated TRAP+ cells, counting both positive and negative 
cells. A minimum of 3000 total cells was counted for each culture condition, in each experiment. To determine 
whether the addition of medium derived from CLL B cells cultures (1 × 106 CLL B cells × 72 h) could increase the 
formation of osteoclasts from monocytes purified from healthy donors, CD14+ monocytes were purified from 
PBMCs of healthy donors by the use of CD14-conjugated magnetic beads following manufacturer’s instructions. 
(Milteny). 1 × 105 cells/well of purified CD14+ cells were thus seeded in a 24 well plate with RPMI1640 + FCS10%. 
After one day, recombinant human MCSF (25 ng/ml) and RANKL (25 ng/ml) were added to these cultures and 
after 3 more days each well was refeeded with new culture medium additioned of MCSF + RANKL. After further 
3 days, conditioned media (CM) from CLL B cells cultures were added together with a suboptimal concentration 
of MCSF and RANKL and after 7 days more the plates were examined for the presence of TRAP+ multinucleated 
cells, as described above. Each experiment was performed in duplicate.
Statistical Analysis. All data were reported as means of ± standard deviation or proportions, as appropriate. 
Unpaired or paired t tests were used to compare data in different groups or in the same group, as appropriate. 
Univariate and Multivariate Linear regression analyses were performed by using the least squares method. A p 
value of less than 0.05 was considered statistically significant. All statistical analyses were carried out by using a 
dedicated software package (SPSS, version 20; SPSS, Chicago, Ill).
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